13 11 20

Information and support

  • Get informed
  • Get support
  • Cut my risk
  • Get involved
  • Research
  • MK3475-716

    Acronym: 

    KeyNote 716

    ACTRN/NCT /ethics: 

    Scientific title: 

    Summary of trial and patient characteristics

    Cancer Type Melanoma & other skin
    Trial Type Treatment
    Phase Phase III Tumour Stream Melanoma
    Age Range 18 years and older Cancer Stage Locally Recurrent or Locally Advanced
    Sex Both Anticipated Start Date
    Molecular Target Anticipated End Date
    Cancer Type Melanoma & other skin
    Trial Type Treatment
    Phase Phase III
    Age Range 18 years and older
    Sex Both
    Molecular Target
    Tumour Stream Melanoma
    Cancer Stage Locally Recurrent or Locally Advanced
    Anticipated Start Date
    Anticipated End Date

    Trial Summary

    Adjuvant therapy with pembrolizumab versus placebo in resected high-risk stage II melanoma: a randomised, double-blind phase III study. Inclusion criteria: surgically resected new diagnosis of stage Iib or Iic cutaneous melanoma; must have T stage T3b, T4a or T4b with pathologically confirmed negative sentinel lymph node biopsy and no evidence of regional (NO) or distant mets (MO); no previous treatment or radiotherapy; no more than 12 weeks from surgery

    Lay Summary

    Sponsor / Cooperative group

    Merck Sharp & Dohme Corp.

    Participating Hospitals

    Hospital Clinical Trial Coordinator Email Phone Principal Investigator Recruitment Status
    Royal Adelaide Hospital Anne Milton anne.milton@sa.gov.au 08 7074 2342 Brown Not Yet Recruiting
    Ashford Cancer Centre Research Helen Daykin hdaykin@adelaidecancercentre.com.au 08 8292 2240 Recruiting